PUBLISHER: DelveInsight | PRODUCT CODE: 1397396
PUBLISHER: DelveInsight | PRODUCT CODE: 1397396
"POLIVY Drug Insight and Market Forecast - 2032" report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the POLIVY for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the POLIVY for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
POLIVY (polatuzumab vedotin-piiq) is a CD79b-directed antibody-drug conjugate (ADC) consisting of three components: the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; the small molecule anti-mitotic agent MMAE; and a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-amino benzyloxy carbonyl (mc-VC-PAB) that covalently attaches MMAE to the polatuzumab antibody. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell-specific surface protein component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable the intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis. POLIVY is being developed by Roche using Seagen ADC technology and is being investigated for treating several types of NHL.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of POLIVY for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.